key: cord-0968269-59pzzxnv
authors: White, Nicholas J; Strub-Wourgaft, Nathalie; Faiz, Abul; Guerin, Philippe J
title: Guidelines should not pool evidence from uncomplicated and severe COVID-19
date: 2021-03-23
journal: Lancet
DOI: 10.1016/s0140-6736(21)00469-4
sha: 98e7ae9daeec8fe74f6bee1764d27b0b502a55bc
doc_id: 968269
cord_uid: 59pzzxnv

nan

to patients with uncomplicated COVID-19 in the community is not supported by current evidence. COVID-19 reflects a changing pathological process. Viral burden peaks early, around the time of first symptoms. This timepoint is when antiviral drugs are likely to be most beneficial. Thereafter, viral burden declines and inflammatory processes dominate in those patients who deteriorate and require admission to hospital, and ultimately respiratory support. Immune modulators and anti-inflammatories are more likely to be of benefit at this later stage but might be harmful if used earlier (ie, by enhancing viral replication). 2 Evidence reviews 2 and the guidelines that they generate 1 should recognise that, although SARS-CoV-2 is one virus, both the COVID-19 disease process and access to health care vary widely. The WHO Global Development Group "prioritized outcomes taking a patient perspective". 2 They decided that mortality would be most important to patients, followed by need for and duration of mechanical ventilation. We argue that prevention of hospital admission is the therapeutic priority for low-resource settings, which usually have few facilities for intensive care. Efficacy assessments in prevention and in uncomplicated COVID-19 should not be pooled with results from severely ill patients who have been admitted to hospital.

WHO. Therapeutics and COVID-19: living guideline

A living WHO guideline on drugs for COVID-19

Dexamethasone in hospitalized patients with COVID-19-preliminary report

We declare no competing interests.